Company Filing History:
Years Active: 1987-2003
Title: The Innovative Contributions of Wu-Nan Wu
Introduction
Wu-Nan Wu is a notable inventor based in Landsdale, Pennsylvania, with a significant impact in the field of pharmaceutical innovations. He holds three patents that showcase his expertise in developing compounds with various therapeutic applications. His work primarily focuses on creating agents that can address critical health issues, including pain management and diabetes treatment.
Latest Patents
Wu's latest patents include the invention of 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives. This invention is directed towards compounds that serve as δ-opioid or μ-opioid receptor modulators. Depending on their agonist or antagonist effects, these compounds can be utilized as analgesics, immunosuppressants, anti-inflammatory agents, and treatments for neurological and psychiatric conditions. Additionally, they have potential applications in managing drug and alcohol abuse, gastritis, diarrhea, cardiovascular issues, and respiratory diseases. Another significant patent involves a hypoglycemic method using 5-substituted pyrrolidinylidene compounds. These compounds are designed to act as hypoglycemic agents, particularly in the treatment of diabetes, similar to linogliride.
Career Highlights
Wu-Nan Wu has worked with prominent companies in the pharmaceutical industry, including McNeil AB and Ortho-McNeil Pharmaceutical Corporation. His experience in these organizations has contributed to his development of innovative solutions in drug formulation and therapeutic applications.
Collaborations
Throughout his career, Wu has collaborated with esteemed colleagues, including Joyce E. Epps and Kung-Tat Ng. These partnerships have likely enhanced his research and development efforts, leading to successful patent applications.
Conclusion
Wu-Nan Wu's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving health outcomes. His work continues to influence the development of new therapeutic agents that address critical medical needs.